Edition:
United States

People: Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.75AUD
19 Oct 2017
Change (% chg)

$0.03 (+1.45%)
Prev Close
$1.73
Open
$1.75
Day's High
$1.77
Day's Low
$1.73
Volume
546,683
Avg. Vol
842,003
52-wk High
$3.41
52-wk Low
$1.06

Weiner, Ben-Zion 

Dr. Ben-Zion Weiner, Ph.D., is an Non-Executive Independent Director of Mesoblast Ltd. In a 37-year career at Teva Pharmaceutical Industries Ltd, he held various senior research and development positions, including Senior Vice President of Global Research and Development. Dr Weiner twice received the Rothschild Prize for industrial innovation – for the development of Copaxone for the treatment of multiple sclerosis, and alpha D3 for kidney and bone disorders. He is on the Board of Directors at Novaremed Ltd., the scientific advisory board at E-QURE Corp. and Breed IT, Corp. and has served on the Board of Directors at Geffen Biomed Investments Ltd (2010-2013), XTL Biopharmaceuticals Limited (2012-2013) and Breed IT, Corp.

Basic Compensation

Total Annual Compensation, AUD 138,250
Restricted Stock Awards, AUD --
Long-Term Incentive Plans, AUD --
All Other, AUD 42,737
Fiscal Year Total, AUD 180,987

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --